UPDATE: Vivos Therapeutics (VVOS) PT Lowered to $4 at Roth Capital

May 20, 2022 9:18 AM EDT
Get Alerts VVOS Hot Sheet
Price: $1.37 +1.48%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 12 | New: 20
Trade Now! 
Join SI Premium – FREE
(Updated - May 20, 2022 9:19 AM EDT)

Roth Capital analyst Scott Henry lowered the price target on Vivos Therapeutics (NASDAQ: VVOS) to $4.00 (from $8.00) while maintaining a Buy rating.

The analyst comments "VVOS reported 1Q22 results that were at the lower end of expectations. Key takeaways from the quarter, in our opinion, include: 1) revenue of $3.5M trailed our target (likely hurt by a challenging dental environment); 2) the company's shift towards the DSO channel could enhance the business model longer-term; and 3) we now target a 2023 equity financing given lower forecasts. Maintain Buy rating with a $4.00/share price target (reduced from $8.00, based on lower forecasts and increased equity dilution)."


You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Roth Capital